IgA Nephropathy – Market Access and Reimbursement Insights Report – 2025

IgA Nephropathy Market Access and Reimbursement Insights

Thelansis’s “IgA Nephropathy Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.

IgA Nephropathy Overview

IgA nephropathy (IgAN) is the most prevalent form of primary glomerulonephritis worldwide. The fundamental issue of this condition lies in the abnormal glycosylation of O-linked glycans (glycoproteins) within the hinge region of IgA1 throughout the body. Consequently, there are increased galactose-deficient IgA1 (GdIgA1) levels in the bloodstream, targeted by glycan-specific IgA and IgG autoantibodies. IgA, an antibody integral to mucosal immunity, occurs in two isotypes, namely IgA1 and IgA2. It can also exist as a dimeric structure known as secretory IgA. Plasma cells mainly produce secretory IgA in a polymeric form, consisting of multiple monomers linked by the J-chain, a 17-kDa polypeptide. In IgAN, the kidneys sustain the primary damage. The disease follows a gradual yet relentless clinical course, leading to end-stage renal disease (ESRD) in approximately 30-40% of patients within 20-30 years. IgAN can manifest in sporadic cases (90-95%) or familial cases (5-10%). Individuals with familial IgAN may experience a more unfavorable prognosis than those with sporadic forms since they are more likely to progress to renal failure.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.

*Survey and interview discussion guide are customized based on client requirements

Deliverables format:

• PowerPoint presentation

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Key business questions answered:

• Market access and reimbursement for current therapies
• Coverage on plans
• Market access restrictions
• Rebates and contracting
• Factors influencing formulary access
• HEOR requirements and influence, etc.
• Expected market access and reimbursement for key emerging therapies
• Level of awareness
• Anticipated coverage on plans
• Factors that would improve market access
• Pricing, etc.
• Impact on brand use
• Key factors driving and limiting brand use
• Best and worst performers on market access, etc.
• Evolving environment
• Payer expectations from emerging therapies
• New policies and their expected impact, etc.
• Advise to drug manufacturers and developers

Read more: IgA Nephropathy – Market Access and Reimbursement Insights Report – 2025